We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CBER CITES NOVO NORDISK FOR MISLEADING PROMOTIONAL ADS
CBER CITES NOVO NORDISK FOR MISLEADING PROMOTIONAL ADS
August 18, 2004
The FDA’s Center for Biologics Evaluation and Research (CBER) has issued a warning letter to Novo Nordisk Pharmaceuticals for promotional materials that failed to include risk information and made misleading safety claims about its NovoSeven coagulant product.